Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2009 Mar 10;100(5):680-3. doi: 10.1038/sj.bjc.6604940. Epub 2009 Feb 17.

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

Author information

1
Glasgow Royal Infirmary, Section of Surgery, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, UK. smtovey@doctors.org.uk

Abstract

We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.

PMID:
19223897
PMCID:
PMC2653773
DOI:
10.1038/sj.bjc.6604940
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center